Biofrontera has presented data from three pivotal Phase III trials for its lead drug candidate BF 200 ALA (5-aminolevulinic acid)...
Gliolan is indicated in adults for visualisation of malignant tissue during surgery for malignant glioma (WHO grade III and IV).
Dignitana, a world leader in medical scalp-cooling technology, announced that the FDA has granted the company’s de novo application to...
Novartis has announced that the FDA has approved a label update for Cosentyx (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved...
Novartis has presented new Cosentyx (secukinumab) data from the prospective the Phase III SCALP study which showed significant improvement in...
The acute hepatic porphyrias (AHP) are a group of four inherited diseases of heme biosynthesis. They present with similar severe, episodic, acute neurovisceral symptoms due to abnormally elevated levels of porphyrin precursors delta-aminolevulinic acid (ALA).
Arcutis Biotherapeutics, Inc. announced it had enrolled the first patient in its single Phase III clinical trial evaluating topical roflumilast foam (ARQ-154) as a potential treatment for scalp and body psoriasis.
Adults with severe alopecia areata (AA) who took Olumiant (baricitinib) achieved significant scalp, eyelash and eyebrow hair regrowth and nearly 75% of those who responded to Olumiant 4-mg achieved 90% scalp coverage at 52 weeks, Eli Lilly and Company and Incyte announced at the American Academy of Dermatology (AAD) Annual Meeting.